At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 471 enrolled
Drug / intervention
Ultra-Rapid Lispro +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
In Brief
A Phase 3 clinical trial evaluating Ultra-Rapid Lispro and Insulin Lispro for Type 1 Diabetes Mellitus. Completed, enrolled 471 participants across 83 sites in 11 countries.
Detailed Summary
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus
CountriesAustralia, Austria, Canada, France, Germany, Hungary, Israel, Italy, Puerto Rico, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartFeb 2019
Primary CompletionJan 2020
TodayJul 2026
First PostedFeb 5, 2019
Enrollment StartFeb 14, 2019
Primary CompletionJan 6, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.4 years ago
Interventions
Ultra-Rapid Lisprodrug
Administered SC
Insulin Lisprodrug
Administered SC